Its announcement comes over the heels of an analogous licensing arrangement presented in February to Adastra Labs, which experienced until now centered on crafting cannabis extracts. Adastra's license also enables it to create and market psilocybin and psilocin – hallucinogens much more frequently often known as magic mushrooms that develop effec